76924-94-2

Usage

InChI:InChI=1/C10H18O4/c1-3-5-10(13-6-7-14-10)8-9(11)12-4-2/h3-8H2,1-2H3

Upstream product

• 107-21-1 ethylene glycol 
• 3249-68-1 ethyl butyroyl acetate 
• 122-51-0 orthoformic acid triethyl ester 
• 141-97-9 ethyl acetoacetate 
• 72546-06-6 5-butanoyl-2,2-dimethyl-1,3-dioxane-4,6-dione 

Downstream Products

• 127743-28-6 2-(2-propyl-1,3-dioxolan-2-yl)ethanol 
• 267241-54-3 (-)-(S_S)-1-(p-tolylsulfinyl)-4-(1,3-dioxolane)-2-oxo-heptane 
• 267241-56-5 (2R,4S)-1-((S)-Toluene-4-sulfinyl)-heptane-2,4-diol 
• 267241-59-8 (S)-5-[(S)-2-(tert-Butyl-diphenyl-silanyloxy)-pentyl]-dihydro-furan-2-one 
• 267241-53-2 2-{5-[2-(tert-butyl-diphenyl-silanyloxy)-pentyl]-dihydro-furan-2-ylidene}-propionic acid tert-butyl ester 
• 721923-22-4 (4R,6R)-6-(4-methoxybenzyloxy)oct-7-en-4-ol 
• 721923-23-5 (4R,6R)-6-(4-methoxybenzyloxy)oct-7-en-4-yl hex-5-enoate 
• 1021151-15-4 N-(4-hydroxy-2-methylphenyl)-3-oxododecanoyl amide 
• 1021151-19-8 N-(4-hydroxy-2-methylphenyl)-3,3-ethyleneglycosyldodecanoyl amide 
• 267241-55-4 (-)-(2R,S_S)-1-(p-tolylsulfinyl)-4-(1,3-dioxolane)-heptane-2-ol 
• 561276-81-1 (-)-(2S,S_S)-1-(p-tolylsulfinyl)-4-(1,3-dioxolane)-heptane-2-ol 
• 267241-61-2 (-)-(2R,S_S)-1-(p-tolylsulfinyl)-4-heptanone-2-ol 

Relevant academic research and scientific papers

Sodium borohydride/methoxydiethylborane mediated syn-1,3-stereoselective total synthesis of herbarumin-III

A simple and efficient stereoselective total synthesis of 10-membered macrolide, herbarumin-III is described. The key steps involved in this synthesis are the selective terminal alkylation of ethyl acetoacetate with ethyl bromide, Sharpless epoxidation, NaBH4/Et2BOMe mediated stereoselective syn-1,3-asymmetric reduction, esterification and olefin metathesis.

AMIDE COMPOUND AND BACTERIAL DISEASE CONTROL AGENT FOR AGRICULTURAL AND HORTICULTURAL USE

The present invention provides an amide compound having antibacterial activity, and a bacterial infection control agent for agricultural and horticultural use that contains the amide compound. The novel amide compound of the present invention is represented by General Formula (1): wherein R is a -CH(R1)(R2) or a -CO(R2) group, R1 is a hydrogen atom or a hydroxyl group, and R2 is a C1-12 alkyl group.

6,8,10-UNDECATRIEN-(3 OR 4)-ONE AND PERFUME COMPOSITION

This invention offers 6,8,10-undecatrien-3-one or 6,8,10-undecatrien-4-one which are represented by the following formula (1) [in the formula, either one of A and B stands for carbonyl group and the other stands for methylene group, and the wavy line signifies cis-form, trans-form, or a mixture of cis- and trans-form at an optional ratio] and which can reproduce an odor rich in naturality and freshness.

6,8,10-UNDECATRIEN-3-OL OR 6,8,10- UNDECATRIEN-4-OL, AND PERFUME COMPOSITION

This invention offers 6,8,10-undecatrien-3-ol and 6,8,10-undecatrien-4-ol. These compounds possess not only woody green note, but also fruity note rich in naturality and freshness, and aroma compositions blended therewith are useful for imparting fragrance and flavor to food and beverage, perfumed cosmetics, medicaments and the like.

AMIDE COMPOUND, SALT THEREOF, AND BIOFILM REMOVER USING THEM

The present invention provides a biofilm stripping agent for removing biofilms already formed. The biofilm stripping agent of the present invention contains, as an active ingredient, an amide compound or salt thereof denoted by General Formula (1), wherein R is a C1-11 alkyl group, and Q is a substituent denoted by the following Formulas (Q1), (Q2) or (Q3), wherein, in Formula (Q1), n is an integer ranging from 0 to 4; in Formula (Q2), R1 is a C1-4 alkyl group, and R2 is a hydroxyl group or carbamoyl group; in Formula (Q3), R3 is a hydrogen atom, hydroxyl group or carbamoyl group.

Benzimidazole compound

An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R1 and R3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R4, R5, R6 and R7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.

Polysubstituted oxygen heterocycles by a Reformatsky-type reaction/reductive cyclization approach from enantiopure β-ketosulfoxides

(Chemical Equation Presented) The stereoselective synthesis of tetrasubstituted tetrahydrofurans and trisubstituted tetrahydropyrans bearing a sulfoxide was achieved by reductive cyclization (Et3SiH/TMSOTf) from the corresponding enantiopure hydroxy ketones protected as a dioxolane. These derivatives are easily accessible from a Reformatsky-type reaction between α-bromo-α′-sulfinyl ketones and protected α- or β-ketoaldehydes, followed by diastereoselective reduction of the resulting β-ketosulfoxide.

ACYL HOMOSERINE LACTONES FOR INHIBITION OF CELL GROWTH

The present invention provides a method for inhibiting the growth of cancer cells using AHLs of the general formula CX-homoserine lactone where "X" represents a number of between 5 and 14 carbon atoms in the acyl chain of the AHL. The method comprises the step of administering to an individual an amount of an AHL effective to inhibit the growth of cancer cells. Also provided is a method for enhancing the effect of a chemotherapeutic agent comprising the step of administering to an individual the chemotherapeutic agent and an amount of an AHL effective to enhance the cancer cell growth inhibitory effect of the chemotherapeutic agent.

New insights into the reduction of β,δ-diketo-sulfoxides

New developments in the reduction of β,δ-diketo-sulfoxides, a reaction that affords important key intermediates for total synthesis, are described. We showed without ambiguity using NMR experiments, that the β-carbonyl group is totally enolised. This result is inconsistent with the previous hypothesis, which supposed the other tautomer (enolisation at the δ-position) as the major one. We propose a rationale to explain the side reactions occurring during the reduction of unprotected β,δ-diketo-sulfoxides and showed that judicious protection of the δ-carbonyl group gave all diastereoisomers of β-hydroxy-δ-ketosulfoxides.

Regio- and diastereoselective synthesis of lissoclinolide analogues by Lewis acid catalyzed cyclization of the first 1,5-bis(trimethylsilyloxy)-1,3,5-hexatrienes with oxalyl chloride

The Lewis acid catalyzed cyclization of 1,5-bis(trimethylsilyloxy)-1,3,5-hexatrienes with oxalyl chloride resulted in formation of polyunsaturated butenolides.